

Human Growth Hormone Drugs: Market Research Report

https://marketpublishers.com/r/HA07779AC1EEN.html

Date: December 2017

Pages: 158

Price: US\$ 5,450.00 (Single User License)

ID: HA07779AC1EEN

Abstracts

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US\$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 28 companies including many key and niche players such as -

Eli Lilly and Company

Ferring Holding SA

Genentech, Inc.

GeneScience Pharmaceuticals Co., Ltd.

Merck KgaA



Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Market Outlook

Evolution of Recombinant Human Growth Hormones (hGH)

Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small

Strong Innovation Drive Takes Hold of the hGH Industry

Sizing the Market

Key Growth Drivers

High Prevalence of Growth Hormone Deficiency Disorders

Innovations Hold the Key to Market Growth

New Indications for hGH Replacement Therapy

Major Growth Restraining Factors

Complex Delivery System

High Cost of hGH Treatment

Difficulty in Securing Reimbursement

Biosimilars Threaten Revenue Growth Erosion

Limited Pharmacological Differences Exist Among Current Agents

2. MARKET TRENDS & ISSUES

Pediatric GHD Rules, while Adult GHD Remains Underserved

Table 1. Worldwide Recombinant Human Growth Hormone Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Turner Syndrome & Idiopathic Short Stature; Pediatric GHD; and Others (includes corresponding Graph/Chart)

Long-Acting hGH Drugs – a Potential Game Changer Select Long-Acting hGH Products in Pipeline by Development Stage Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth



Table 2. Worldwide Biosimilar Demand by Product Category (2013): Percentage Breakdown of Value Sales for Epoetina, Granulocyte Colony-Stimulating Factors (G-CSFs), Interferons, Insulins, Low Molecular Weight Heparins (LMWH), Recombinant Human Growth Hormones (rhGHs), and Others (includes corresponding Graph/Chart)

Manufacturers Bet on Novel Drug Delivery Technologies
Phase IV Studies Necessitated for First Biosimilars
Needle-less Drug Delivery Systems to Wipe Out of Syringes
Drug Delivery Device Options for Marketed hGH Products
Growing Non-Prescription/Off-Label Usage – A Potential Health Hazard
Oral hGH Secretagogues – An Alternative to Controversial hGH Injections in
Professional Sports
Risk of Cancer Necessitates Judicious Use of hGH in Children
Dose Titration – A Key to Achieve Enhanced Tolerability
Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE

hGH – A Highly Consolidated Market

Table 3. Leading Recombinant hGH Products in the Global Market (2015): Annual Sales in US\$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen (includes corresponding Graph/Chart)

Overview of Select Leading Marketed hGH Products

Norditropin

Genotropin

Humatrope

Saizen

Omnitrope – the Somatropin Biosimilar

Somatropin Biopartners

Review of Select hGH Products in Pipeline

OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market

Somavaratan Advances Further in Clinical Trials

Somapacitan Moves Ahead in Development; Nears Commercial Launch

TransCon hGH – the Potential Blockbuster hGH Product in Waiting

4. HUMAN GROWTH HORMONE: AN OVERVIEW



5. RECENT INDUSTRY ACTIVITY

NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing

Ascendis Pharma Commences Phase III Trial on TransCon hGH
Teijin Inks License Deal with Versartis for Somavaratan
JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject Liquid

Formulations

Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen Versartis Commences Phase II/III Studies for VRS-317 in Japan Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone Hanmi Introduces Development-Stage Long Acting hGH Novo Nordisk Obtains FDA Approval for Norditropin FlexPro Prefilled Pen OPKO and Pfizer Ink Agreement for Development of OPKO's Long-acting hGH-CTP Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children

6. FOCUS ON SELECT GLOBAL PLAYERS

Eli Lilly and Company (US)
Ferring Holding SA (Switzerland)
Genentech, Inc. (US)
GeneScience Pharmaceuticals Co., Ltd. (China)
Merck KgaA (Germany)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (US)
Sandoz International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 5. World Historic Review for Human Growth Hormone Drugs by Geographic



Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 6. World 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market AnalysisCurrent & Future AnalysisUS hGH Market – A Peek into GHD Prevalence and Cost of Treatment

Table 7. US Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)

Table 8. US hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Idiopathic Short Stature, Pediatric GHD, Turner Syndrome and Others (includes corresponding Graph/Chart)

FDA Approvals Clear Way for Treating More Children
Major hGH Drugs Available in the US, and FDA Approved Indications
US FDA Promotes rhGH Development through Orphan Drug Designation
FDA Approval of First Biosimilar
Omnitrope Versus Genotropin – A US Perspective
FDA Issues First Draft of Guidelines for Biosimilar and Interchangeable Biologicals
FDA Regulations Governing hGH Products in the OTC Drugs Market
Alarming Increase in Sales of hGH Drugs for Anti-Ageing Therapy
Strategic Corporate Developments
Select Key Players
B. Market Analytics



Table 9. The US Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 10. The US Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

Market Analysis

Table 11. Canadian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 12. Canadian Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

A. Market AnalysisCurrent & Future AnalysisMarket Overview

Table 13. Japanese Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)

Table 14. Japanese hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Pediatric GHD and Others (includes corresponding Graph/Chart)

Competition in the Japanese hGH Market

Table 15. Key Players in the Japanese hGH Market (2012, 2014 & 2016): Percentage



Breakdown of Value Sales for Eli Lilly, JCR, Novo Nordisk, Pfizer and Others (includes corresponding Graph/Chart)

Timeline of Major Approvals for JCR Pharmaceutical's hGH Product Growject Japanese Biosimilar Regulatory Guidelines
Sandoz' Omnitrope – the First Biosimilar hGH Launched in Japan
Strategic Corporate Developments
B. Market Analytics

Table 16. Japanese Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 17. Japanese Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

A. Market AnalysisCurrent & Future AnalysisPediatric GHD – Leading Target Indication for hGH Products

Table 18. European Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)

Table 19. European hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Pediatric GHD and Others (includes corresponding Graph/Chart)

European hGH Market Focuses on Product Differentiation to Revitalize Sales Regulations Pertaining to Biosimilars in the EU

Table 20. Adoption Rates for hGH Biosimilar in Major Western Europe Markets: 2016 (includes corresponding Graph/Chart)



New Indications Could Drive Growth B. Market Analytics

Table 21. European Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 22. European Historic Review for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 23. European 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4A. FRANCE

Market Analysis

Table 24. French Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 25. French Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market AnalysisCurrent & Future AnalysisStrategic Corporate DevelopmentKey PlayersB. Market Analytics

Human Growth Hormone Drugs: Market Research Report



Table 26. German Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 27. German Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 28. Italian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 29. Italian Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

Market Analysis

Table 30. The UK Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 31. The UK Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis



Table 32. Spanish Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 33. Spanish Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4F. REST OF EUROPE

A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
Select Key Players
B. Market Analytics

Table 34. Rest of Europe Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 35. Rest of Europe Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Biosimilar Regulations In Asian Countries
South Korea
China
India

Genescience Pharmaceuticals Co., Ltd. – A Leading Chinese Player B. Market Analytics



Table 36. Asia-Pacific Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 37. Asia-Pacific Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

Market Analysis

Table 38. Rest of World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

Table 39. Rest of World Historic Review for Human Growth Hormone Drugs Market Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 28 (including Divisions/Subsidiaries - 33)

The United States (10)

Canada (1)

Japan (2)

Europe (10)

Germany (4)

The United Kingdom (2)

Rest of Europe (4)

Asia-Pacific (Excluding Japan) (9)

Middle East (1)



I would like to order

Product name: Human Growth Hormone Drugs: Market Research Report
Product link: https://marketpublishers.com/r/HA07779AC1EEN.html

Price: US\$ 5,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/HA07779AC1EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970